Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $5.29, but opened at $5.65. Aclaris Therapeutics shares last traded at $5.5320, with a volume of 337,251 shares trading hands.
Analyst Ratings Changes
Several research firms have recently commented on ACRS. Piper Sandler lifted their price objective on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Thursday, March 19th. Guggenheim assumed coverage on Aclaris Therapeutics in a research note on Tuesday, May 5th. They issued a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Wednesday, June 24th. Finally, UBS Group set a $10.00 price objective on Aclaris Therapeutics in a research note on Thursday, April 16th. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $11.50.
Check Out Our Latest Stock Analysis on ACRS
Aclaris Therapeutics Stock Down 0.1%
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $2.00 million during the quarter, compared to analyst estimates of $1.32 million. Aclaris Therapeutics had a negative net margin of 832.58% and a negative return on equity of 55.89%. As a group, equities research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total value of $1,359,000.00. Following the completion of the sale, the insider owned 13,950,000 shares in the company, valued at approximately $63,193,500. This trade represents a 2.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.80% of the stock is owned by insiders.
Hedge Funds Weigh In On Aclaris Therapeutics
Several hedge funds have recently made changes to their positions in ACRS. Bank of New York Mellon Corp lifted its stake in Aclaris Therapeutics by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock worth $776,000 after acquiring an additional 3,507 shares during the period. Raymond James Financial Inc. boosted its holdings in Aclaris Therapeutics by 2.2% in the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock valued at $539,000 after acquiring an additional 6,217 shares in the last quarter. Rhumbline Advisers increased its position in Aclaris Therapeutics by 7.4% during the 3rd quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 6,271 shares during the period. ProShare Advisors LLC increased its position in Aclaris Therapeutics by 45.4% during the 4th quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 6,734 shares during the period. Finally, Intech Investment Management LLC raised its holdings in Aclaris Therapeutics by 19.8% in the 4th quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 7,702 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.
Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.
Read More
- Five stocks we like better than Aclaris Therapeutics
- 3 European Stocks to Carry Investors Through the Back Half of 2026
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
- Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push
- 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
